Advertisement
Organisation › Details
GeneQuine Biotherapeutics GmbH
GeneQuine Biotherapeutics GmbH is a biotech company focused on the development of innovative gene therapies for treatment of musculoskeletal disorders. GeneQuine’s aim is to use its gene therapy platform to established sustained production of therapeutic proteins locally in the tissues or organs where they are needed. The lead candidate GQ-303 is being developed as a locally administered treatment for osteoarthritis and has demonstrated the potential to be a symptomatic and disease-modifying treatment in several animal models. In 2017, Flexion Therapeutics, Inc. acquired GeneQuine’s then-lead program for osteoarthritis, which is based on the same gene therapy vector technology as GQ-303 and is currently in clinical Phase 1 testing. GeneQuine is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium. *
Start | 2011-08-31 established | |
Group | GeneQuine (Group) | |
Industry | gene therapy | |
Industry 2 | HDAd vector platform | |
Person | Guse, Kilian (GeneQuine Biotherapeutics 201210 Managing Director) | |
Region | Hamburg | |
Country | Germany | |
Street | 6-12 Harburger Schloßstr. | |
City | 21079 Hamburg | |
Tel | +49-40-76629-2853 | |
Address record changed: 2022-09-17 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: High-Tech Gründerfonds Management GmbH. (1/26/21). "Press Release: GeneQuine Biotherapeutics Secures more than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases". | ||
Record changed: 2023-12-30 |
Advertisement
More documents for GeneQuine (Group)
- [1] High-Tech Gründerfonds Management GmbH. (1/26/21). "Press Release: GeneQuine Biotherapeutics Secures more than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases"....
- [2] High-Tech Gründerfonds Management GmbH. (12/14/17). "Press Release: GeneQuine Biotherapeutics’ Gene Therapy Program for Treatment of Knee Osteoarthritis Acquired by Flexion Therapeutics"....
- [3] Flexion Therapeutics, Inc.. (12/13/17). "Press Release: Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee". Burlington, MA....
- [4] Merck KGaA. (1/23/17). "Press Release: Merck Announces Emerging Biotech Grant Program Winners". Darmstadt....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top